Episode 5 explores a diverse array of Series A funding rounds, starting with Allink Biotherapeutics securing $42 million, providing insights into their biotherapeutic advancements. Celosia Therapeutics' Series A funding is highlighted for its focus on ALS gene therapy. The episode also features Constrafor's impressive $264 million Series A, driving innovation in the construction industry. Additionally, Roon's Series A funding is covered, emphasizing expansion in women's health information, alongside Doron Therapeutics' Series A earmarked for Phase 3 clinical studies in osteoarthritis.

(0:00) Welcome and introduction

(0:16) Allink Biotherapeutics' $42 million Series A and company insights

(3:21) Celosia Therapeutics' Series A funding for ALS gene therapy

(5:04) Constrafor's $264 million Series A and construction industry innovation

(8:19) Roon's Series A funding and expansion in women's health information

(11:34) Doron Therapeutics' Series A for Phase 3 clinical studies in osteoarthritis

(14:02) Episode wrap-up and call to action